Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 6, 2002 - Issue 2
Submit an article Journal homepage
660
Views
82
CrossRef citations to date
0
Altmetric
Miscellaneous

Biochemical aspects in autism spectrum disorders: updating the opioid-excess theory and presenting new opportunities for biomedical intervention

Paul Whiteley Autism Research Unit, School of Sciences (Health), University of Sunderland, Sunderland, SR2 7EE, UK, Tel: +44 (0)191 510 8922; , Fax: +44 (0)191 567 0420; , E-mail: [email protected]
&
Paul Shattock Autism Research Unit, School of Sciences (Health), University of Sunderland, Sunderland, SR2 7EE, UK, Tel: +44 (0)191 510 8922; , Fax: +44 (0)191 567 0420; , E-mail: [email protected]
Pages 175-183 | Published online: 25 Feb 2005

Bibliography

  • American Psychiatric Association diagnostic criteria from DSM-IV. American Psychiatric Association, Washington, DC, USA (1994).
  • The autistic spectrum - a handbook. NAS, London UK (1999).
  • WING L: The definition and prevalence of autism: a review. Eur. I Ch. Adol. Psychia. (1993) 2:61–74.
  • GIOVANARDI ROSSI P, POSAR A, PARMEGGIANI A: Epilepsy in adolescents and young adults with autistic disorder. Brain Dev. (2000) 22:102–106.
  • TAYLOR B, MILLER E, FARRINGTON CP etal.: Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet (1999) 353:2026–2029.
  • •Epidemiological survey on the prevalence of ASD in the north Thames region of the UK.
  • CHAKRABARTI S, FOMBONNE E: Pervasive developmental disorders in preschool children. 1. Am. Med. Assoc. (2001) 285:3093–3099.
  • MAGNUSSON P, SAEMUNDSEN E: Prevalence of autism in Iceland. j Autism Dev. Disord. (2001) 31:153–163.
  • SHATTOCK P, WHITELEY P, TODD L: Is there an increasing incidence of Autism? evidence and possible explanations. (2001) (In Press).
  • LOYNES F: The rising challenge: a survey of local education authorities on educational provision for pupils with autistic spectrum disorders. A report by the all party parliamentary group on autism. NAS, London UK (2001).
  • RASMUSSEN P, BORJESSON 0, WENTZ E, GILLBERG C: Autistic disorders in Down's syndrome: background factors and clinical correlates. Dev. Med. Ch. Neural (2001) 43:750–754.
  • LE COUTEUR A, BAILEY A, GOODE S etal.: A broader phenotype of autism: the clinical spectrum in twins. 1. Ch. Psycho]. Psychia. (1996) 37:785–801.
  • COOK EH JR, COURCHESNE R, LORD C etal.: Evidence of linkage between the serotonin transporter and autistic disorder. Mal Psychia. (1997) 3:247–250.
  • PERSICO AM, D'AGRUMA L, MAIORANO N et al.: Reelin gene alleles and haplotypes as a factor predisposing to autistic disorder. Mal Psychia. (2001) 6:150–159.
  • ASHERSON PJ, CURRAN S: Approachesto gene mapping in complex disorders and their application in child psychiatry and psychology. Br. J. Psychia. (2001) 179:122–128.
  • PANKSEPP J: A neurochemical theory of autism. Trends Neurosci. (1979) 2:174–177.
  • ••Original paper that first proposed theopioid-excess theory of autism.
  • GILLBERG C, TERENIUS L, LONNERHOLM G: Endorphin activity in childhood psychosis. Spinal fluid levels in 24 cases. Arc. Gen. Psychia. (1985) 42:780–783.
  • CAZZULLO AG, MUSETTI MC, MUSETTI L, BAJO S, SACERDOTE P, PANERAI A: Beta-endorphin levels in peripheral blood mononuclear cells and long-term naltrexone treatment in autistic children. Eur. Neuropsychapharmacal. (1999) 9:361–366.
  • NELSON KB, GRETHER JK, CROEN LA et al.: Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. Ann. Neural (2001) 49:597–606.
  • PERRY EK, LEE ML, MARTIN-RUIZ CM et a/.:Cholinergic activity in autism: abnormalities in the cerebral cortex and basal forebrain. Am. 1. Psychia. 158: 1058-1066 (2001) .
  • LEBOYER M, PHILIPPE A, BOUVARD M et al.: Whole blood serotonin and plasma beta-endorphin in autistic probands and their first-degree relatives. Biol. Psychia. (1999) 45:158–163.
  • BOUVARD MP, LEBOYER M, LAUNAY JM etal.: Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study. Psychia. Res. (1995) 58:191–201.
  • PANKSEPP J, LENSING P: Brief report: a synopsis of an open-trial of naltrexone treatment of autism with four children. 1. Autism Develop. Dis. (1991) 21:243–249.
  • KOLMEN BK, FELDMAN HM, HANDEN BL, JANOSKY JE: Naltrexone in young autistic children: replication study and learning measures. 1. Am. Acad. Ch. Adol. Psychia. (1997) 36:1570–1578.
  • SHATTOCK PEG, KENNEDY A, ROWELL F, BERNEY TP: The role of neuropeptides in autism and their relationship with classical neurotransmitters. Brain Dysfurr. (1990) 3:328–345.
  • ••Original HPLC analytical method fordetecting urinary peptides.
  • SHATTOCK P, LOWDON G: Proteins, peptides and autism. Part 2: Implications for the education and care of people with autism. Brain Dysfurr. (1991) 4:323–334.
  • ••Overview of the biochemical andbehavioural effects of the opioid-excess theory of autism.
  • WHITELEY P, RODGERS J, SAVERY D, SHATTOCK P: A gluten-free diet as an intervention for autism and associated spectrum disorders: preliminary findings. Autism (1999) 3:45–65.
  • WARING RH, KLOVRZA LV: Sulphur metabolism in autism. 1. Env Med. (2000) 10:25–32.
  • •Biochemical findings on levels of urinary/ plasma sulfate in autism.
  • SHATTOCK P, WHITELEY P: How dietary intervention could ameliorate the symptoms of autism. Pharma. 1 (2001) 267.
  • GARDNER ML: Absorption of intact proteins and peptides. Biol. Rev (1994) 59:289–311.
  • BANKS WA, KASTIN AJ: Peptide transport systems for opiates across the blood-brain barrier. Am. 1. Physial. (1990) 259:E1–E10.
  • REICHELT KL, HOLE K, HAMBERGER A et al.: Biologically active peptide containing fractions in schizophrenia and childhood autism. Adv. Bia. Psychopharm. (1981) 28:627–643.
  • ••Advancement of the opioid-excess theoryof autism.
  • PERSICO AM, MILITERNI R, BRAVACCIO C et al.: Adenosine deaminase alleles and autistic disorder: case control and family-based association studies. Am. 1. Med. Gen. (2000) 96:784–790.
  • HORVATH K, STEFANATOS G, SOKOLSKI KN, WACHTEL R, NABORS L, TILDON JT: Improved social and language skills after secretin administration in patients with autistic spectrum disorders. 1. Ass. Acad. Nlin. Physicians (1998) 9:9–15.
  • •First published report on the use of secretin on three children with autism.
  • ROBERTS W, WEAVER L, BRIAN J et al.: Repeated doses of porcine secretin in the treatment of autism: a randomized, placebo-controlled trial. Pediatrics (2001) 107:E71.
  • CONIGLIO SJ, LEWIS JD, LANG C et al.: A randomized, double-blind, placebo-controlled trial of single-dose intravenous secretin as treatment for children with autism. j Pediatrics (2001) 138:649–655.
  • FRENHANI PB, BURINI RC: Mechanism of action and control in the digestion of proteins and peptides in humans. Arq. Castroenteral (1999) 36:139–147.
  • D'EUFEMIA E CELLI M, FINOCCHARIO R et al.: Abnormal intestinal permeability in children with autism. Acta Paediatrica (1996) 85:1076–1079.
  • •First report of abnormal intestinal permeability in people with autism.
  • WARING RH, NGONG JM, KLOVRZA L, GREEN S, SHARP H: Biochemical parameters in autistic children. Develop. Brain Dysfun. (1997) 10:40–43.
  • ALBERTI A, PIRRONE E ELIA M, WARING RH, ROMANO C: Sulphation deficit in low-functioning' autistic children: a pilot study. Biol. Psychia. (1999) 46:420–424.
  • HORVATH K, PAPADIMITRIOU JC, RABSZTYN A, DRACHENBERG C, TILDON JT: Gastrointestinal abnormalities in children with autistic disorder. j Pediatrics (1999) 135:533–535.
  • WAKEFIELD AJ, MURCH SH, ANTHONY A et al.: Ileal-nodular hyperplasia, non-specific colitis and pervasive developmental disorder in children. Lancet (1998) 351:637–641.
  • ••First publication reporting the presence ofinflammatory bowel disease (IBD) in children with ASD.
  • WAKEFIELD AJ, ANTHONY A, MURCH SH et al: Enterocolitis in children with developmental disorders. Am. Castroenteral (2000) 95:2285–2295.
  • ••Follow-up study on the presence of IBD inchildren with ASD.
  • SABRA S, BELLANTI JA, COLON AR:Ileal-nodular hyperplasia, non-specific colitis and pervasive developmental disorder in children. Lancet (1998) 352:234–235.
  • FURLANO RI, ANTHONY A, DAY R et al.: Colonic CD8 and gamma delta T-cell infiltration with epithelial damage in children with autism. I Pediatrics (2001) 138:366–372.
  • •First published report on gut epithelial dysfunction in autism.
  • KAWASHIMA H, MORI T, KASHIWAGI Y, TAKEKUMA K, HOSHIKA A, WAKEFIELD A: Detection and sequencing of measles virus from peripheral mononuclear cells from patients with inflammatory bowel disease and autism. D4. Dis. Sci. (2000) 45:723–729.
  • •Identification of the measles virus in PBMC of people with ASD and IBD.
  • SINGH VK, LIN SX, YANG VC: Serological association of measles virus and human herpesvirus-6 with brain autoantibodies in autism. Clin. Immune] Immunapathal (1998) 89:105–108.
  • UHLMANN V, MARTIN C, SHEILS 0 et al.: Potential viral pathogenic mechanism for new variant inflammatory bowel disease. (2002) (In Press).
  • ••Identification of the measles virus inintestinal tissue samples from children with ASD and IBD.
  • WHITCOMB DC, TAYLOR IL: A new twist in the brain-gut axis. Am. I Med. Sci. (1992) 304: 334–338.
  • MM KS, WASS CA, CROSS AS: Blood-brain barrier permeability during the development of experimental bacterial meningitis in the rat. Exp. Neural. (1997) 145:253–257.
  • EGLETON RD, MITCHELL SA, HUBER JD, PALIAN MM, POLT R, DAVIS TP: Improved blood-brain barrier penetration and enhanced analgesia of an opioid peptide by glycosylation. Pharmacy] Exp. Therapeu. (2001) 299:967–972.
  • GILLBERG IC: Autistic syndrome with onset at age 31 years: herpes encephalitis as a possible model for childhood autism. Develop. Med. Ch. Neural. (1991) 33:920–924.
  • BARAK Y, KIMHI R, STEIN D, GUTMAN J, WEIZMAN A: Autistic subjects with comorbid epilepsy: a possible association with viral infections. Child Psychia. Human Develop. (1999) 29:245–251.
  • REICHELT KL, SAELID G, LINDBACK T, BOLER JB: Childhood autism: a complex disorder. Biol. Psychia. (1986) 21:1279–1290.
  • CADE R, PRIVETTE M, FREGLY M et al.: Autism and schizophrenia: intestinal disorders. Nut. Neurosci. (1999) 2:57–72.
  • PAGE T, COLEMAN M: Purine metabolism abnormalities in a hyperuricosuric subclass of autism. Biochimica et Biophysica Acta (BBA) Mal Basis Dis. (2000) 1500:291–296.
  • MORENO-FUENMAYOR H, BORJAS L, ARRIETA A, VALERA V, SOCORRO-CANDANOZA L: Plasma excitatory amino acids in autism. Invest. Clin. (1996) 37:113–128.
  • ISRANGKUN PP, NEWMAN HA, PATEL ST, DURUIBE VA, ABOU-ISSA H: Potential biochemical markers for infantile autism. Neurochem. Pathal (1986) 5:51–70.
  • PEDERSEN OS, LIU Y, REICHELT KL: Serotonin uptake stimulating peptide found in plasma of normal individuals and in some autistic urines. I Pep. Res. (1999) 53:641–646.
  • REICHELT KL, KNIVSBERG A-M, LIND G, NODLAND M: Probable aetiology and possible treatment of childhood autism. Brain Dysfun. (1991) 4:308–319.
  • ••Overview of urinary findings and use ofdietary intervention in ASD.
  • MILLS MJ, SAVERY D, SHATTOCK PEG: Rapid analysis of low levels of indoly1-3-acryloylglycine in human urine by high-performance liquid chromatography. I Chromat. B. (1998) 712:51–58.
  • •Analytical assays developed to detect JAG in urine.
  • ANDERSON RJ, BENDALL DJ, GARNETT I et al.: Identification of indoly1-3-acryloylglycine (JAG) in the urine of people with autism. j Pharm. Pharmacy] (2002) 54:295–8.
  • MARKLOVA E: Where does indolylacrylicacid come from? Anatho Addy (1999) 17:401–413.
  • CASTEJON 0J, MARCANO DE HIDALGO A et al.: Imbalance of plasma amino acids in patients with autism and subjects with attention deficit hyperactivity disorder. Rev Neural. (2001) 33:401–408.
  • BELL JG, SARGENT JR, TOCHER DR, DICK JR: Red blood cell fatty acid compositions in a patient with autisticspectrum disorder: a characteristic abnormality in neurodevelopmental
  • •• disorders? Prostaglan. Leukomierres Ess. Fatty Acids (2000) 63:21–25.
  • SHAW KNF: Dependence on urinary indole excretion in Hartnups disease upon gut flora. Fed. Proc. (1960) 19:194.
  • US AW, MCLAUGHLIN I, MCLAUGHLIN RK, LIS EW, STUBBS EG: Profiles of ultraviolet-absorbing components of urine from autistic children, as obtained by high-resolution ion-exchange chromatography. OM. Chem. (1976) 22:1528–1532.
  • SANDLER RH, FINEGOLD SM, BOLTE ER et al.: Short-term benefit from oral vancomycin treatment of regressive-onset autism. j Child Neural. (2000) 15:429–435.
  • ANDERSON RJ, CARR K, CAIRNS D et al.: Putting tryptophan in the spotlight (2002) In press.
  • JAMAL GA: Neurological syndromes of organophosphorus compounds. Ad. Drug React. Toxicolog. Rev (1997) 16:133–170.
  • MACCREADY RA: Admissions of phenylketonuric patients to residential institutions before and after screening programs of the newborn infant. Pediatrics (1974) 85:383–385.
  • KOCH R, FISHLER K, AZEN GG, HENDERSON R, FREIDMAN EG: Psychoeducational findings among children treated for phenylketonuria. Am. j Men. Del (1987) 92:65–73.
  • CHALLACOMBE D: When is a coeliac? Lancet (1994) 343:188–200.
  • COLLIN E PIRTILLA T, NURMIKKO T: Coeliac disease, brain atrophy and dementia. Neurology (1991) 4:427–431.
  • VLISSIDES DN, VENULET A, JENNER FA: A double-blind gluten-free/ gluten-load controlled trial in a secure ward population Br .j Psychia. (1986) 148:447–452.
  • DOHAN FC, GRASSBERGER JC, LOWELL FM, JOHNSON HT, ARBEGAST AW: Relapsed schizophrenics: more rapid improvement on a milk and cereal free diet. Br .j Psychia. (1969) 115:595–596.
  • WING L: Feeding problems in autism. Communication (1987) 21:7–9.
  • WHITELEY E RODGERS J, SHATTOCK P: Feeding patterns in autism. Autism (2000) 4:207–211.
  • RAITEN DJ, MASSARO T: Perspectives on the nutritional ecology of autistic children. I Autism Develop. Disord. (1986) 16:133–143.
  • MERCER ME, HOLDER MD: Food cravings, endogenous opioid peptides, and food intake: a review. Appetite (1997) 29:325–352.
  • KNIVSBERG A-M, REICHELT KL, NODLAND M: Reports on dietary intervention in autistic disorders. Nut. Neurosci. (2001) 4:25–37.
  • KNIVSBERG A-M, WIIG K, LIND G, NODLAND M, REICHELT KL: Dietary intervention in autistic syndromes. Brain Dysfurr. (1990) 3:315–317.
  • ••Open trial on the use of gluten- andcasein-free diets with people with ASD.
  • KNIVSBERG A-M, REICHELT KA, NODLAND M, HOIEN T: Autistic syndromes and diet: a follow-up study Scandin. J Ed. Res. (1995) 39:223–236.
  • ••Four year follow-up of an open trial on theuse of gluten- and casein-free diets with people with ASD.
  • LUCARELLI S, FREDIANI T, ZINGONI AM etal.: Food allergy and infantile autism. Pariminerva Medina (1995) 37:137–141.
  • GOBBI G, BOUQUET F, GRECO L etal.: Coeliac disease, epilepsy, and cerebral calcifications. The italian working group on coeliac disease and epilepsy. Lancet (1992) 340:439–443.
  • O'BANION D, ARMSTRONG B, CUMMINGS RA, STANGE J: Disruptive behavior: a dietary approach. J. Autism Childhood Schizo. (1978) 3:325–337.
  • ROWE KS, ROWE KJ: Synthetic food coloring and behaviour: a dose response effect in a double-blind placebo-controlled, repeated-measures study. j Pediatrics (1994) 125:691–698.
  • SHAW W KASSEN E, CHAVES E: Increased urinary excretion of analogs of Krebs cycle metabolites and arabinose in two brothers with autistic features. Clin Chem. (1995) 41:1094–1104.
  • BARON-COHEN S, BOLTON P: Autism: The Facts. Oxford University Press, Oxford, UK (1993).
  • GIACOMETTI A, CIRIONI 0, BALDUCCI M et al.: Epidemiologic features of intestinal parasitic infections in Italian mental institutions Eur. j Epidemiol. (1997) 13:825–830.
  • DUVAUX-MIRET 0, DISSOUS C, GAUTRON JP, PATTOU E, KORDON C, CAPRON A: The helminth Schistosoma mansoni expresses a peptide similar tohuman beta-endorphin and possesses a proopiomelanocortin-related gene. New Biol. (1990) 1:93–99.
  • DUVAUX-MIRET 0, STEFANO GB, SMITH EM, DISSOUS C, CAPRON A: Immunosuppression in the definitive and intermediate hosts of the human parasite Schistosoma mansoni by release of immunoactive neuropeptides. Proc. Nati Acad. Li. USA (1992) 89:778–781.
  • TAYLOR SD, SOUDAH HC, CHEY WY, SCHEIMAN JM: Duodenal acidification and secretin, but not intraduodenal fat, inhibit human gastric acid secretion via prostaglandins. Gastroenterology (1994) 107:1680–1685.
  • KONTUREK SJ, KWIECIEN N, OBTULOWICZ W et al.: Effect of enkephalin and naloxone on gastric acid and serum gastrin and pancreatic polypeptide concentrations in humans. Gut (1983) 24:740–745.
  • JIN HO, ZHOU L, LEE KY, CHANG TM, CHEY WY: Inhibition of acid secretion by electrical acupuncture is mediated via beta-endorphin and somatostatin Am. j Physiol. (1996) 271:G524–G530.
  • IMPROTA G, BROCCARDO M: Effect ofselective mu 1, mu 2 and delta 2 opioid receptor agonists on gastric functions in the rat. Neuropharmacology (1994) 33:977–981.
  • MEHALL JR, NORTHROP R, SALTZMAN DA, JACKSON RJ, SMITH SD: Acidification of formula reduces bacterial translocation and gut colonization in a neonatal rabbit model. ..J. Pediatric Sur. (2001) 36:56–62.

Websites

  • www.mrc.ac.uldpdf-autism-report.pdf The Medical Research Council report on autism.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.